Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer

Junyl Hwang, Sang Hee Cho, Jeong Shim Hyun, Se Ryeon Lee, Sook Ahn Jae, Duk Hwan Yang, Yeo Kyeoung Kim, Je Jung Lee, Hyeoung Joon Kim, Ik Joo Chung

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

This phase II study evaluated the efficacy and safety of combination chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer. Patients with histologically confirmed gastric adenocarcinoma were eligible for the study. Paclitaxel (175 mg/m2) and cisplatin (75 mg/m2) were given as a 1-hr intravenous infusion on day 1, followed by 5-FU (750 mg/m2) as a 24-hr continuous infusion for 5 days. This cycle was repeated every 3 weeks. Forty-five eligible patients (median age, 56 yr) were treated in this way. Of the 41 patients in whom efficacy was evaluable, an objective response rate (ORR) was seen in 51.2% (95% CI, 0.35-0.67), a complete response in two, and a partial response in 19 patients. The median progression free survival was 6.9 months (95% CI, 5.86-7.94 months), and the median overall survival was 12.7 months (95% CI, 9.9-15.5). The main hematological toxicity was neutropenia and greater than grade 3 neutropenia was observed in twelve patients (54%). Febrile neutropenia developed in three patients (6.8%). The major non-hematological toxicities were asthenia and peripheral neuropathy, but most of patients showed grade 1 or 2. In conclusion, combination chemotherapy with paclitaxel, cisplatin, and 5-FU is a promising regimen, and was well tolerated in patients with advanced gastric cancer.

Original languageEnglish
Pages (from-to)586-591
Number of pages6
JournalJournal of Korean Medical Science
Volume23
Issue number4
DOIs
Publication statusPublished - 2008 Aug 1
Externally publishedYes

Fingerprint

Combination Drug Therapy
Fluorouracil
Stomach Neoplasms
Neutropenia
Asthenia
Febrile Neutropenia
TP protocol
Peripheral Nervous System Diseases
Paclitaxel
Intravenous Infusions
Cisplatin
Disease-Free Survival
Stomach
Adenocarcinoma
Safety
Survival

Keywords

  • Cisplatin
  • Fluorouracil
  • Paclitaxel
  • Stomach neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. / Hwang, Junyl; Cho, Sang Hee; Hyun, Jeong Shim; Lee, Se Ryeon; Jae, Sook Ahn; Yang, Duk Hwan; Kim, Yeo Kyeoung; Lee, Je Jung; Kim, Hyeoung Joon; Chung, Ik Joo.

In: Journal of Korean Medical Science, Vol. 23, No. 4, 01.08.2008, p. 586-591.

Research output: Contribution to journalArticle

Hwang, Junyl ; Cho, Sang Hee ; Hyun, Jeong Shim ; Lee, Se Ryeon ; Jae, Sook Ahn ; Yang, Duk Hwan ; Kim, Yeo Kyeoung ; Lee, Je Jung ; Kim, Hyeoung Joon ; Chung, Ik Joo. / Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer. In: Journal of Korean Medical Science. 2008 ; Vol. 23, No. 4. pp. 586-591.
@article{90e47a0a1d2d44b19602e8520cb940bb,
title = "Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer",
abstract = "This phase II study evaluated the efficacy and safety of combination chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer. Patients with histologically confirmed gastric adenocarcinoma were eligible for the study. Paclitaxel (175 mg/m2) and cisplatin (75 mg/m2) were given as a 1-hr intravenous infusion on day 1, followed by 5-FU (750 mg/m2) as a 24-hr continuous infusion for 5 days. This cycle was repeated every 3 weeks. Forty-five eligible patients (median age, 56 yr) were treated in this way. Of the 41 patients in whom efficacy was evaluable, an objective response rate (ORR) was seen in 51.2{\%} (95{\%} CI, 0.35-0.67), a complete response in two, and a partial response in 19 patients. The median progression free survival was 6.9 months (95{\%} CI, 5.86-7.94 months), and the median overall survival was 12.7 months (95{\%} CI, 9.9-15.5). The main hematological toxicity was neutropenia and greater than grade 3 neutropenia was observed in twelve patients (54{\%}). Febrile neutropenia developed in three patients (6.8{\%}). The major non-hematological toxicities were asthenia and peripheral neuropathy, but most of patients showed grade 1 or 2. In conclusion, combination chemotherapy with paclitaxel, cisplatin, and 5-FU is a promising regimen, and was well tolerated in patients with advanced gastric cancer.",
keywords = "Cisplatin, Fluorouracil, Paclitaxel, Stomach neoplasms",
author = "Junyl Hwang and Cho, {Sang Hee} and Hyun, {Jeong Shim} and Lee, {Se Ryeon} and Jae, {Sook Ahn} and Yang, {Duk Hwan} and Kim, {Yeo Kyeoung} and Lee, {Je Jung} and Kim, {Hyeoung Joon} and Chung, {Ik Joo}",
year = "2008",
month = "8",
day = "1",
doi = "10.3346/jkms.2008.23.4.586",
language = "English",
volume = "23",
pages = "586--591",
journal = "Journal of Korean Medical Science",
issn = "1011-8934",
publisher = "Korean Academy of Medical Science",
number = "4",

}

TY - JOUR

T1 - Phase II study of paclitaxel, cisplatin, and 5-fluorouracil combination chemotherapy in patients with advanced gastric cancer

AU - Hwang, Junyl

AU - Cho, Sang Hee

AU - Hyun, Jeong Shim

AU - Lee, Se Ryeon

AU - Jae, Sook Ahn

AU - Yang, Duk Hwan

AU - Kim, Yeo Kyeoung

AU - Lee, Je Jung

AU - Kim, Hyeoung Joon

AU - Chung, Ik Joo

PY - 2008/8/1

Y1 - 2008/8/1

N2 - This phase II study evaluated the efficacy and safety of combination chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer. Patients with histologically confirmed gastric adenocarcinoma were eligible for the study. Paclitaxel (175 mg/m2) and cisplatin (75 mg/m2) were given as a 1-hr intravenous infusion on day 1, followed by 5-FU (750 mg/m2) as a 24-hr continuous infusion for 5 days. This cycle was repeated every 3 weeks. Forty-five eligible patients (median age, 56 yr) were treated in this way. Of the 41 patients in whom efficacy was evaluable, an objective response rate (ORR) was seen in 51.2% (95% CI, 0.35-0.67), a complete response in two, and a partial response in 19 patients. The median progression free survival was 6.9 months (95% CI, 5.86-7.94 months), and the median overall survival was 12.7 months (95% CI, 9.9-15.5). The main hematological toxicity was neutropenia and greater than grade 3 neutropenia was observed in twelve patients (54%). Febrile neutropenia developed in three patients (6.8%). The major non-hematological toxicities were asthenia and peripheral neuropathy, but most of patients showed grade 1 or 2. In conclusion, combination chemotherapy with paclitaxel, cisplatin, and 5-FU is a promising regimen, and was well tolerated in patients with advanced gastric cancer.

AB - This phase II study evaluated the efficacy and safety of combination chemotherapy with paclitaxel, cisplatin, and 5-fluorouracil (5-FU) in advanced gastric cancer. Patients with histologically confirmed gastric adenocarcinoma were eligible for the study. Paclitaxel (175 mg/m2) and cisplatin (75 mg/m2) were given as a 1-hr intravenous infusion on day 1, followed by 5-FU (750 mg/m2) as a 24-hr continuous infusion for 5 days. This cycle was repeated every 3 weeks. Forty-five eligible patients (median age, 56 yr) were treated in this way. Of the 41 patients in whom efficacy was evaluable, an objective response rate (ORR) was seen in 51.2% (95% CI, 0.35-0.67), a complete response in two, and a partial response in 19 patients. The median progression free survival was 6.9 months (95% CI, 5.86-7.94 months), and the median overall survival was 12.7 months (95% CI, 9.9-15.5). The main hematological toxicity was neutropenia and greater than grade 3 neutropenia was observed in twelve patients (54%). Febrile neutropenia developed in three patients (6.8%). The major non-hematological toxicities were asthenia and peripheral neuropathy, but most of patients showed grade 1 or 2. In conclusion, combination chemotherapy with paclitaxel, cisplatin, and 5-FU is a promising regimen, and was well tolerated in patients with advanced gastric cancer.

KW - Cisplatin

KW - Fluorouracil

KW - Paclitaxel

KW - Stomach neoplasms

UR - http://www.scopus.com/inward/record.url?scp=50449093139&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=50449093139&partnerID=8YFLogxK

U2 - 10.3346/jkms.2008.23.4.586

DO - 10.3346/jkms.2008.23.4.586

M3 - Article

VL - 23

SP - 586

EP - 591

JO - Journal of Korean Medical Science

JF - Journal of Korean Medical Science

SN - 1011-8934

IS - 4

ER -